文献速递流行病学与生物统计临床试验与 GCP

儿童与青少年抑郁及自杀风险筛查:美国预防服务工作组更新证据报告与系统综述

Screening for Depression and Suicide Risk in Children and Adolescents: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
PubMed 文献 · JAMA · 2022-01-01

本系统综述纳入抑郁筛查21项研究(N=5433)和自杀风险19项研究(N=6290),评估筛查工具准确性及干预效果。抑郁筛查工具灵敏度0.59-0.94、特异度0.38-0.96;心理治疗和药物治疗对抑郁有部分获益且无统计学显著危害,但自杀风险筛查工具和干预的证据有限。

要点

  • 抑郁筛查工具灵敏度0.59-0.94、特异度0.38-0.96,部分工具检测抑郁的准确性尚可。
  • 心理治疗改善抑郁症状(BDI合并SMD -0.58),药物治疗改善症状(CDRS-R合并MD -3.76)。
  • 自杀风险筛查工具和干预的证据有限,筛查直接健康结局的研究未报告。

核心结论

  • 间接证据提示部分筛查工具检测抑郁的准确性尚可。
  • 心理治疗和药物治疗对抑郁有部分获益且无统计学显著危害,但自杀风险筛查工具和干预的证据有限。

研究设计与样本

  • 系统综述纳入英文随机临床试验、诊断准确性研究、心理治疗和一线药物治疗随机试验、报告危害的随机试验、观察性研究和系统综述。
  • 检索PubMed、Cochrane Library、PsycINFO、CINAHL和试验注册库至2021年7月19日,并检索参考文献、专家和监测至2022年6月1日。
  • 抑郁筛查纳入21项研究(N=5433),自杀风险纳入19项研究(N=6290)。
  • 由两名评价者评估标题摘要、全文文献和研究质量并提取数据,当至少3项相似研究可用时进行Meta分析。

主要发现

  • 抑郁筛查无研究报告筛查对健康结局的直接影响,7项研究(n=3281)报告筛查工具灵敏度0.59-0.94、特异度0.38-0.96。
  • 心理治疗与抑郁症状改善相关(贝克抑郁量表合并标准化均数差-0.58 [95% CI, -0.83至-0.34];n=471;4项研究;汉密尔顿抑郁量表合并均数差-2.25 [95% CI, -4.09至-0.41];n=262;3项研究)。
  • 心理治疗与临床应答相关(3项研究使用不同阈值获得统计学显著结果),与丧失诊断相关(相对风险1.73 [95% CI, 1.00至3.00;n=395;4项研究])。
  • 药物治疗与症状改善相关(儿童抑郁评定量表修订版均数差-3.76 [95% CI, -5.95至-1.57;n=793;3项研究]),与缓解相关(相对风险1.20 [95% CI, 1.00至1.45;n=793;3项研究]),与功能改善相关(儿童全球评估量表合并均数差2.60 [95% CI, 0.78至4.42;n=793;3项研究])。
  • 自杀风险筛查无研究报告筛查对健康结局的直接获益,2项随机对照试验(n=2675)报告筛查无危害;1项研究(n=581)报告筛查灵敏度0.87-0.91、特异度0.60;16项随机对照试验(n=3034)报告自杀风险干预,干预与贝克绝望量表评分降低相关(合并均数差-2.35 [95% CI, -4.06至-0.65];n=644;4项随机对照试验)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 抑郁筛查无研究报告筛查对健康结局的直接影响。
  • 自杀风险筛查无研究报告筛查对健康结局的直接获益,自杀风险筛查工具和干预的证据有限。
  • 药物治疗与安慰剂相比,自杀相关结局和不良事件差异无统计学意义。
  • 自杀相关其他结局的发现不一致或无统计学显著差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Depression, suicidal ideation, and self-harm behaviors in youth are associated with functional impairment and suicide. OBJECTIVE: To review the evidence on screening for depression or suicide risk in children and adolescents to inform the US Preventive Services Task Force (USPSTF). DATA SOURCES: PubMed, Cochrane Library, PsycINFO, CINAHL, and trial registries through July 19, 2021; references, experts, and surveillance through June 1, 2022. STUDY SELECTION: English-language, randomized clinical trials (RCTs) of screening for depression or suicide risk; diagnostic test accuracy studies; RCTs of psychotherapy and first-line pharmacotherapy; RCTs, observational studies, and systematic reviews reporting harms. DATA EXTRACTION AND SYNTHESIS: Two reviewers assessed titles/abstracts, full-text articles, and study quality and extracted data; when at least 3 similar studies were available, meta-analyses were conducted. MAIN OUTCOMES AND MEASURES: Test accuracy, symptoms, response, remission, loss of diagnosis, mortality, functioning, suicide-related events, and adverse events. RESULTS: Twenty-one studies (N = 5433) were included for depression and 19 studies (N = 6290) for suicide risk. For depression, no studies reported on the direct effects of screening on health outcomes, and 7 studies (n = 3281) reported sensitivity of screening instruments ranging from 0.59 to 0.94 and specificity from 0.38 to 0.96. Depression treatment with psychotherapy was associated with improved symptoms (Beck Depression Inventory pooled standardized mean difference, -0.58 [95% CI, -0.83 to -0.34]; n = 471; 4 studies; and Hamilton Depression Scale pooled mean difference, -2.25 [95% CI, -4.09 to -0.41]; n = 262; 3 studies) clinical response (3 studies with statistically significant results using varying thresholds), and loss of diagnosis (relative risk, 1.73 [95% CI, 1.00 to 3.00; n = 395; 4 studies). Pharmacotherapy was associated with improvement on symptoms (Children's Depression Rating Scale-Revised mean difference, -3.76 [95% CI, -5.95 to -1.57; n = 793; 3 studies), remission (relative risk, 1.20 [95% CI, 1.00 to 1.45]; n = 793; 3 studies) and functioning (Children's Global Assessment Scale pooled mean difference, 2.60 (95% CI, 0.78 to 4.42; n = 793; 3 studies). Other outcomes were not statistically significantly different. Differences in suicide-related outcomes and adverse events for pharmacotherapy when compared with placebo were not statistically significant. For suicide risk, no studies reported on the direct benefits of screening on health outcomes, and 2 RCTs (n = 2675) reported no harms of screening. One study (n = 581) reported on sensitivity of screening, ranging from 0.87 to 0.91; specificity was 0.60. Sixteen RCTs (n = 3034) reported on suicide risk interventions. Interventions were associated with lower scores for the Beck Hopelessness Scale (pooled mean difference, -2.35 [95% CI, -4.06 to -0.65]; n = 644; 4 RCTs). Findings for other suicide-related outcomes were mixed or not statistically significantly different. CONCLUSION AND RELEVANCE: Indirect evidence suggested that some screening instruments were reasonably accurate for detecting depression. Psychotherapy and pharmacotherapy were associated with some benefits and no statistically significant harms for depression, but the evidence was limited for suicide risk screening instruments and interventions.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Viswanathan M, Wallace IF, Cook Middleton J, et al. Screening for Depression and Suicide Risk in Children and Adolescents: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2022. PMID: 36219399. doi:10.1001/jama.2022.16310

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。